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Summary Expression of c-erbB3 protein was investigated in 104 primary breast carcinomas comprising nine comedo ductal carcinoma in
situ (DCIS), 91 invasive ductal carcinomas and four invasive lobular carcinomas using two monoclonal antibodies, RTJ1 and RTJ2. Of the 91
invasive ductal carcinomas, seven contained the comedo DCIS component adjacent to the invasive component. An immunohistochemical
technique was used to evaluate the association between expression of c-erbB3 and clinical parameters and tumour markers such as
epidermal growth factor receptor (EGFR), c-erbB2, cathepsin-D and p53 in archival formalin-fixed paraffin-embedded tumour tissues. Our
results indicated that RTJ1 and RTJ2 gave identical staining pattems and concordant results. It was found that the overexpression of c-erbB3
protein was observed in 67% (6/9) of comedo DCIS, 52% (44/84) of invasive ductal carcinomas, 71% (5/7) of carcinomas containing both the
in situ and invasive lesions and 25% (1/4) of invasive lobular carcinomas. A significant relationship (P < 0.05) was observed between strong
immunoreactivity of c-erbB3 protein and histological grade, EGFR and cathepsin-D, but not with expression of c-erbB2, p53, oestrogen
receptor status, lymph node metastases or age of patient. However, we noted that a high percentage of oestrogen receptor-negative tumours
(59%), lymph node-positive tumours (63%) and c-erbB2 (63%) were strongly positive for c-erbB3 protein. We have also documented that a
high percentage of EGFR (67%), c-erbB2 (67%), p53 (75%) and cathepsin-D-positive DCIS (60%) were strongly positive for c-erbB3. These
observations suggest that overexpression of c-erbB3 protein could play an important role in tumour progression from non-invasive to invasive
and, also, that it may have the potential to be used as a marker for poor prognosis of breast cancer.
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C-erbB3. a new member of the erbB type I family of tyrosine
kinase receptors. has been mapped to human chromosome
12qll-13 (Kraus et al. 1989). However. the related epidermal
growth factor receptor (EGFR) is located on chromosome
7pl2-13 (Spurr et al. 1984) and the c-erbB2 gene on 17pl'-2 1.3
(Coussens et al. 1985: Popescu et al. 1989). The gene for the c-
erbB3 receptor is transcribed into a 6.2-kb mRNA. which is trans-
lated into the protein and modified by glycosvlation to give a
mature protein of about 160 kDa (Plowman et al. 1990: Prigent
and Gullick. 1992). Recently. it has been shown that heregulilnneu
differentiation factor (NDF) binds to and stimulates the tyrosine
kinase activity ofc-erbB3 (Carrawav et al. 1994).
Expression ofc-erbB3 has been detected in normal human adult
and fetal tissues using polvclonal antibodies (Prigent et al. 1992).
Rajkumar et al (1993) have described the production of a mono-
clonal antibody (RTJI) that is specific for c-erbB3 protein and
reported positive immunostaining in a series of gastrointestinal
tract tumours. Other studies have also demonstrated overexpres-
sion of c-erbB3 protein in breast carcinomas (Lemoine et al.
1992a: Gasparini et al. 1994: Quinn et al. 1994: Travis et al. 1996).
pancreatic cancers (Lemorne et al. 1992b). gastric cancers
(Sanidas et al. 1993). cenical cancer (Hunt et al. 1995: Rajkumar
et al. 1995). prostate cancer (Poller et al. 1992). bladder cancer
(Rajkumar et al. 1996) and ox-arian carcinomas (Mandai et al.
1994: Simpson et al. 1995).
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Expression of EGFR and c-erbB2 receptors and the other
members of the erbB familv has been extensivelv studied in
many different tumours. and it has been found that their oxer-
expression is associated w-ith poor prognosis (Lofts and Gullick.
1991: Gullick. 1991). Elevated levels of EGFR and c-erbB2
has-e been found in breast carcinomas and are often found to
be associated with poor prognosis (Sainsburx et al. 1987: Costa
et al. 1988). Currently. there is little information axailable regard-
ing the expression of c-erbB3 protein in formalin-fixed and
paraffin-embedded primary breast carcinomas. As breast cancer is
an important disease in Malaysia. especially in younger women. we
used this study to evaluate the c-erbB3 expression in Malavsian
breast cancerpatients. The indirect immunoperoxidase method wvas
used to examine the expression of c-erbB3 protein in breast carci-
noma tissues fixed in formalin. We used two different types of
monoclonal antibodies. RTJI (IgM) and RTJ2 (IgG1). which were
raised against the same 49.3-kDa synthetic peptide to detect the c-
erbB3 protein. Here. we report the expression ofc-erbB3 protein in
different histological types ofpnrmary breast carcinomas and relate
it to several clinical parameters. such as oestrogen receptor status.
lymph node status. histological grade and patients' age. and tumour
markers such as EGFR. c-erbB2. cathepsin-D (oestrogen-regulated
protein) and p53 (tumour-suppressor gene).
MATERIALS AND METHODS
Patients and tissues
A consecuti-e series of29 and 75 primary breast carcinomas were
obtained. respectively. from Subang Jaya Medical Centre. Subano
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Jaya. Selangor. Malaysia. and Hospital Kuala Lumpur. Kuala
Lumpur. Malaysia Tumours in most of the patients were detected
symptomatically and only a small proportion were diagnosed
mammographically. with further histological confirmation in both
the hospitals. Patients were treated by wide local excision with
axillary node dissection if the tumour size was less than 4 cm.
Mastectomy was performed when the tumour was more than 4 cm
in size. Tle median tumour size was 2 cm. No treatment had been
given before the tumour was excised. The median number of
nodes retrieved in axillary dissection was 12 nodes for Hospital
Kuala Lumpur and ten nodes for Subang Jaya Medical Centre. In
our study. lymphatic invasion was seen in almost all cases.
Vascular invasion was observed in five cases. The tumours were
fixed in buffered formalin for 12-18 h after surgery. Paraffim
sections of tissues were cut at 5 gm thickness for histological and
immunohistochemical evaluation. Full clinical information was
available for each patient. Ofthe 104 cases ofprimary breast carci-
nomas, nine were ductal carcinoma in situ (DCIS) ofcomedo type,
84 were invasive ductal carcinomas, seven contained both the in
situ and the invasive component and four were invasive lobular
carcinomas. Forty-one of the patients showed lymph node metas-
tases and 54 showed no lymph node involvement. Patients were
grouped into two groups based on age at the time ofdiagnosis: age
<50years and age > 50 years. Sixty-six patients werediagnosed at
age below 50 and 38 were diagnosed at the age of 50 and above.
All the invasive ductal carcinomas were graded using the method
described by Elston (1987). Eighteen of the invasive ductal carci-
nomas were well differentiated (grade I), 43 were moderately
differentiated (grade H) and 30 were poorly differentiated (grade
III). Invasive lobular carcinomas were graded according to the
modified criteria (Elston. 1987) of Bloom-Richardson (Bloom
and Richardson. 1957). All four invasive lobular carcinomas were
poorly differentiated.
Immunohistochemistry
The staining method employed was an indirct immunoperoxidase
system using a standard streptavidin-biotin-peroxidase complex
technique. Immunostaining was performed using two different
antibodies - an IgM mouse monoclonal antibody (clone RTJI)
(NCL-c-erbB3) obtained from Novocastra Lab, UK, and an IgGl
mouse monoclonal antibody (clone RTJ2) from Calbiochem, USA
- which were raised against the synthetic peptide (49.3 kDa) from
the cytoplasmic domain of the human c-erbB3 protein. Other
primary antibodies used were oestrogen receptor(ID5, Dako),p53
(DO 7. Dako), c-erbB2 (polyclonal, Dako), cathepsin-D (poly-
clonal,Dako) andepidermalgrowth factorreceptor(EGFR) (poly-
clonal. Oncogene Science. USA).
The sections were deparaffinized in xylene and rehydrated in
descending concentrations of ethanol. After rinsing in distilled
water. endogenous peroxidase was blocked with 3% hydrogen
peroxide (in water) for 10 min at 37°C. The sections were washed
briefly in phosphate-buffered saline (PBS) pH 7.6 for 5 min. The
sections were incubated with the c-erbB3 primary antibodies
(RTJ1 and RTJ2) (dilution 1:20) for 1.5 h at room temperature.
After the incubation. the slides were washed in PBS for 15 min
and incubated with biotinylated secondary antibody (LSAB/HRP,
Duet. Dako) for 10min at 37°C. After further washing for 5 mi.
the sections were incubated with streptavidin-conjugated peroxi-
dase complex (LSAB/HRP. Duet. Dako) for another 10min at
37°C. The tissue sections were washed again in PBS for S min.
The colour reaction was developed by incubating the sections
with the AEC (3-amino-9-ethylcarbazole) chromogen (Dako) and
counterstained with Mayer's haematoxylin (Fluka. France). The
slides were mounted in aqueous mounting media and examined
under the microscope. Immunostaining was also performed for
EGFR (dilution 1:15, 1 h), c-erbB2 (dilution 1:80, 1.5 h).
cathepsin-D (dilution 1:20, 1 h). p53 and oestrogen receptor (dilu-
tion 1:20.2 h). All the antibodies were diluted in 1% BSA (bovine
serum albumin. Sigma, USA). For p53 and oestrogen receptor, we
used microwave treatment to obtain optimal staining intensity.
Initially, the sections were microwaved twice in 10 mM sodium
citrate buffer (pH 6.0) for 5 min. The slides were cooled at room
temperature for 20 min and washed in PBS before incubating with
the primary antibody. T'he rest of the staining procedures were
followed as above. Breast carcinoma tissues known to react with
the marker were used as positive controls and incubated in each
batch of staining. As for negative control, the primary antibody
was omitted and replaced with PBS and negative control anti-
bodies mouse IgGl (clone DAK-GOI, Dako) and IgM (clone
DAK-G08, Dako). The antibodies were adjusted to the same
concentration as the primary antibody.
Scoring and statistical analysis
The staining for c-erbB3 was cytoplasmic and was assessed
according to the method descnbed by Quinn et al (1994). Negative
staining or equivocal staining was considered as less than normal
expression, weak but defmnite positive staining was considered to
represent normal expression and strong, granular staining indi-
cated overexpression. However, for the purpose of statistical
analysis. only the intensity of staining was considered. Strong
membrane staining for c-erbB2 and epidermal growth factor
receptor (EGFR) and strong cytoplasmic staining for cathepsin-D
were considered to represent overexpression of the gene product.
Tumours that exhibited strong positivity for c-erbB3. c-erbB2,
EGFR and cathepsin-D were included in statistical analysis. For
p53, the tumour scores were based on the method described by
Isola et al (1992). Tumours were scored as strongly positive if
more than 20% of the nuclei were stained. hImmunostaining in
more than 20% of the tumour cells was taken to represent p53
protein overexpression. If only a small proportion of the nuclei
were stained (1-20%), the tumour was scored weakly positive.
Weakly positive and negative tumours were not included in statis-
tical analysis. Oestrogen receptor expression was considered
positive when more than 10% of the tumour cells demonstrated
positive nuclear staining and negative when less than 10% stained
(Pertschuk et al, 1990). This method was used because it has been
demonstrated to be more predictive ofpatients' prognosis.
The chi-squared analysis (contingency tables) was performed
to assess the significance of association between expression of
c-erbB3 and clinicopathological parameters and other tumour
markers. Statistical Graphics System Version 5.0 was used to
conduct the correlation tests. The level of significance used
throughout the statistical test was 0.05 (5%).
RESULTS
In the present study. expression of c-erbB3 protein was detected
using two monoclonal antibodies, RTJ1 and RTJ2. We observed
identical staining for both the antibodies. In general. the staining
was homogeneous in the majority of the tumour cells with mild
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Figure 1 Immunohistochemical analysis of c-erbB3 expression detected by
RTJ1 in paraffin-embedded invasive ductal carcinoma tissue. The intense
staining for the c-erbB3 protein was observed as cytoplasmic staining in the
malignant epithelial cells (magnification x 133)
Figure 2 Expression of c-erbB3 protein was detected by RTJ2
immunohistochemically in paraffin-embedded invasive ductal carcinoma
tissue. Strong staining for c-erbB3 protein was noted in the cytoplasm of the
malignant cells (magnification x 66)
heterogeneous reactivity. The staining for c-erbB3 detected by
both the antibodies was predominantly cytoplasmic, with none of
the tumours exhibiting membrane immunoreactivity. The staining
was finely granular throughout the cytoplasm of the malignant
Table 1 Association between overexpression of c-erbB3 protein detected
by RTJ1 and RTJ2 and clinicopathological parameters
Parameters Total no. of Positive cases for x2
cases (n = 95) c-erbB3 (%)
Oestrogen receptor (ER) statusa
ER+ 27 10 (37) P = 0.06
ER- 68 40 (59) (NS)
Lymph node (N) statusa
N+ 41 26 (63) P= 0.06
N- 54 24 (44) (NS)
Patient age (age at diagnosis)a
<50 years 57 31 (54) P = 0.67
.50 years 38 19 (50) (NS)
Histological grading
Grade 18 4 (22) P= 0.004
Grade II 43 22 (51) (S)
Grade lIl 34 24 (71)
S, significance at P < 0.05. NS, not significant. aNine DCIS cases were not
included in statistical analysis.
epithelial cells, which are shown in Figure 1 (RTJ1) and Figure 2
(RTJ2). Immunopositivity ofc-erbB3 protein was found in 65% of
the 104 primary breast carcinomas. Strong staining, which denotes
overexpression, was seen in 54% (56/104) and weak staining
in 11% (12/104) of the total breast carcinomas studied. No
immunoreactivity was observed in non-malignant cells. Antibody
reactivity was not observed in the stromal cells. No staining was
noted in negative control tissue.
Immunopositivity of c-erbB3 was evaluated in comedo DCIS,
invasive ductal carcinomas, carcinomas with combined lesions (in
situ and invasive ductal component) and invasive lobular carci-
nomas. Ourdata indicated that six (67%) ofthe nine comedo DCIS
were strongly positive for c-erbB3 protein. No weak staining was
seen in the in situ carcinomas. Of the 84 invasive ductal carci-
nomas, 44 (52%) showed strong immunopositivity, whereas seven
(8%) showed weak staining. Among the four invasive lobular
carcinomas, one (25%) was strongly stained and three (75%) were
weakly stained. Immunoreactivity of c-erbB3 protein was also
observed in five (71%) of seven cases in which comedo DCIS was
adjacent to the invasive ductal component. In these cases, both the
in situ and the invasive component were strongly positive. No
weak staining was observed.
Table 1 summarizes the relationship between c-erbB3 expres-
sion (detected by RTJ1 and RTJ2) and prognostic factors including
Table 2 Association between overexpression of c-erbB3 protein detected by RTJ1 and RTJ2 and other tumour markers
Tumour markers Total no. of Presence (+)l No. of positive cases x2
cases (n = 95) absence (-) for c-erbB3 (%)
EGFRa 47 + 32 (68) P= 0.003
48 18 (38) (S)
c-erbB2a 41 + 26 (63) P = 0.07
54 24 (44) (NS)
p53a 31 + 14(45) P=0.31
64 36 (56) (NS)
Cathepsin-Da 56 + 36 (64) P = 0.006
39 14 (36) (S)
S, significance at P < 0.05. NS, not significant. aNine DCIS cases were not included in statistical analysis.
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oestrogen receptor status, lymph node involvement, histological
grade and patients' age. Nine comedo DCIS were analysed sepa-
rately. We did not observe any differences between the antibodies.
Overexpression of c-erbB3 was significantly associated with
poorly differentiated tumours (P = 0.004). We demonstrated that
71% of the grade Ill tumours exhibited strong c-erbB3 positivity.
No significant difference was observed with oestrogen receptor
status (P>0.05), lymph node involvement (P>0.05) and patients'
age (P > 0.05). Although the associations between c-erbB3 and
oestrogen receptor orlymph node status were not supported statis-
tically, we showed that a high percentage of oestrogen receptor-
negative tumours (59%) and lymph node-positive tumours (63%)
were c-erbB3 positive. Coexpression with other tumour markers,
such as EGFR, c-erbB2, p53 and cathepsin-D, was analysed
(Table 2). Our results showed a significant relationship between
overexpression of c-erbB3 protein and EGFR (P = 0.003) and
cathepsin-D (P = 0.006), but not with c-erbB2 (P > 0.05) or p53
(P > 0.05). We found that high percentage of tumours strongly
positive for EGFR (68%) and cathepsin-D (64%) were also
strongly positive for c-erbB3. Sixty three per cent of c-erbB2-
positive tumours were strongly positive for c-erbB3, but the rela-
tionship was not supported statistically. All nine comedo DCIS
obtained from patients below age 50 were negative for oestrogen
receptor. Six ofthese were strongly positive forc-erbB3. Ourdata
on comedo DCIS indicated that 67% (4/6) of EGFR-positive
tumours, 67% (6/9) of c-erbB2-positive tumours, 75% (3/4) of
p53-positive tumours and 60% (3/5) of cathepsin-D-positive
tumours exhibited strong c-erbB3 positivity.
DISCUSSION
Our data showed that over half (54%) of 104 primary breast
carcinomas of various histological types overexpressed c-erbB3
protein, which was detected by RTJ1 and RTJ2. Both the
antibodies gave an identical staining pattem, which suggests the
specificity ofthe antibodies. The staining waspredominantly cyto-
plasmic, with none of the tumours demonstrating membrane
staining. RTJ1, an IgM monoclonal antibody, was shown to give a
betterstaining pattemthan the polyclonal antibody when tested on
formalin-fixed paraffin-embedded tissues or breast cancer cell
lines using the immunohistochemical technique, although it was
shown to detect other proteins of higher molecular weight in
Western blots (Rajkumar et al, 1993). The superiorperfonnance of
RTJ1 could be due to it being an IgM antibody with ten potential
combining sites and a high avidity for multiple copies of the
c-erbB3 protein in tissue sections (Rajkumar et al, 1993). RTJ2,
an IgGl monoclonal antibody directed against the same peptide
(49.3 kDa)(Rajkumar etal, 1995), gave an identical immunohisto-
chemical staining pattern with tissues which had earlier been
stained with RTJ1 (Rajkumar et al, 1993) and rabbit polyclonal
antibody (Prigent et al, 1992). Furthermore, RTJ2 has been shown
to be specific for c-erbB3 protein as determined by Western blot-
ting, immunoprecipitation and immunocytochemistry. Lemoine et
al (1992a) showedgood agreement between the intensity ofsignal
on Norhern blot analysis and the intensity of immunohistochem-
ical staining with the 49.3-kDa polyclonal antibody using breast
cancer and non-breast cancercell lines. In addition,Rajkumaret al
(1993) had shown that breast carcinoma cell lines and non-malig-
nant breast carcinoma cell lines that had been previously shown to
express high, intermediate and low levels of c-erbB3 mRNA
(Lemoine et al, 1992a) demonstrated an identical staining reaction
when stained with the polyclonal antibody (Lemoine et al, 1992a)
and RTJ1. As RTJI and RTJ2 gave concordant results and iden-
tical staining pattems which were also indicated by the present
study, the cytoplasmic staining of RTJ1 could not be due to non-
specific reaction or cross-reaction. In a recent paper on a larger
study with RTJ1, Travis et al (1996) reported that 15% of 346
primary breast cancer cases and 35% of 145 advanced breast
cancer cases showed strong staining for c-erbB3. Previously,
Lemoine et al (1992a) had reported increased expression of
c-erbB3 in 22% of 195 primary infiltraing breast carcinomas. In
another study by Quinn et al (1994), 29% of 97 primary breast
cancer cases demonstrated c-erbB3 overexpression. Poller et al
(1992), using polyclonal antibody and a smaller sample size,
demonstrated that 13 of 14 primary breast carcinomas were
positive for c-erbB3 immunoreactivity but failed to describe the
staining intensity of the positive cells. This makes it difficult to
interpret their data Using RTJ1, these authors had shown that the
staining was observed to be predominantly cytoplasmic. Prigent et
al (1992) has suggested that there is a possibility that the majority
ofc-erbB3 protein at any one time is present in intracellular pools.
Initially, it had been thought that the cytoplasmic immunoreac-
tivity of c-erbB2 was non-specific (de Potter et al, 1989).
However, Kumar et al (1991) had reported that only about 20% of
the total c-erbB2 protein expressed in SKBR-3 breast cancer cells
was located on the cell surface, the remainder being in other intra-
cellular fractions. In addition, Coombs et al (1993) had shown that
the cytoplasmic staining forc-erbB2 can be blocked by the immu-
nizing peptide, suggesting that this represents expression of the
c-erbB2 protein. This could also be one of the possibilities for
c-erbB3. In contrast, Gasparini et al (1994), using the same anti-
body (RTJ1), has reported that 65% of the node-negative breast
carcinomas showed staining of cell membranes, but 13% showed
strong positivity and a much higher percentage (89%) showed
cytoplasmic staining. In addition, the authors have indicated that
there is a highly significant association between membrane and
cytoplasmic staining. In common with other findings, the present
data showed that these antibodies (RTJ1 and RTJ2) locate the
c-erbB3 protein mainly in the cytoplasm, suggesting that
cytoplasmic immunoreactivity may be significant. The high
proportion of breast carcinomas with strongly expressed c-erbB3
indicates that the gene may have an important role in breast
tumorigenesis.
Of the nine ductal carcinoma in situ of comedo subtype,
six (67%) showed overexpression of c-erbB3 gene product.
Interestingly, ductal cacinoma in situ has been shown to be a
precursorofinvasivecarcinomas, because it is frequentlypresent in
tissues adjacent tobreast cancerand is associated with the presence
ofinvasive carcinoma in the same region ofthe same breast where
the DCIS was found (Page et al, 1982; Betsill et al, 1987). Comedo
DCIS, a subtype of DCIS, has been associated with a higher
rate of proliferation, as determined by thymidine labelling index
(TLI), compared with other subtyps of DCIS (Meyer, 1986).
Furthermore, features such as comedo subtype have been demon-
strated to be associated with local recurrence and progression to
invasive breast cancer (Lagios et al. 1989; Lagios, 1990). This
implies that comedo DCIS are biologically aggressive neoplasms.
Based on theseobservations, we suggestthatexpression ofc-erbB3
may be up-regulated during the preinvasive stages and could be an
importantpathogenic factor in early events ofbreast malignancies.
In addition, we have demonstae that five (71%) out of seven
cases in which comedo DCIS were present adjacent to the invasive
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component were strongly stained for c-erbB3 protein in both the
lesions. Similarly. Poller et al ( 1992) have shown that expression of
c-erbB3 was detected in the invasive and in the in situ component
present in the same tumour. This clearlv indicates that expression of
c-erbB3 is not only present in non-invasive staaes. but also main-
tained in the invasive stages. We also noted that a high frequency of
invasive ductal carcinomas (52%-c) showed elevated levels of
c-erbB3 protein. The above information further strengthens our
findings that c-erbB3 may be involved in the progression from
preinvasive to invasive stage. The above observations have an
important implication regarding the role ofc-erbB3 in the initiation
and progression of breast cancer. Elevated levels of c-erbB3 were
seen in one (25%7) invasive lobular carcinoma. but the role of
c-erbB3 in this type of cancer cannot be determined because
ofan insufficient number of samples.
In addition. we have investigated the relationship between
elevated levels of c-erbB3 protein and various clinicopathological
parameters. Our data indicated that overexpression ofc-erbB3 was
significantly associated with high histological grade tumours.
Expression of c-erbB3 was independent of oestrogen receptor
status. nodal involvement and patients' age. although a hiah
percentage of oestrogen receptor-negative tumours (59%7c) and
lymph node-positive tumours (63%7) were strongly positive for c-
erbB3 protein. Lemoine et al (1992a) reported that overexpression
ofc-erbB3 was significantly correlated with the presence oflymph
node metastases. but not with oestrogen receptor status and tumour
grade. In a larger study. Travis et al (1996) were unable to demon-
strate significant association between strong c-erbB3 positivitv-
and oestrogen receptor status. histological grade. lymph node
status or patients age. Similar observation was noted in a smaller
series of 97 malignant breast tumours by Quinn et al (1994). In
lymph node-negative breast cancer patients. Gaspanini et al (1994)
could not show any association between c-erbB3 positivity and
patients age. histological grading or steroid hormone receptors.
However. we were not able to compare our results with those of
last study because the patient groups were different. Furthermore.
Gasparini et al (1994) used membrane staining to interpret the data
but did not determine the association between cvtoplasmic staining
and pathological or other clinical characteristics in order to
observ-e the difference between membrane and cytoplasmic
stainingy. It has been well documented that tumours that lack
oestrogen receptors demonstrate lymph node involvement and
poorly differentiated tumours were associated with poor prog-
nosis. However. our results showed that expression of c-erbB3
protein was significantlv associated with histological grade which
has not been documented previously. These observations indicate
c-erbB3. a new member of the type 1 growth factor receptor
family. may have potential to be an indicator for poor prognosis.
Overexpression of c-erbB3 protein was significantly associated
with EGFR and cathepsin-D. but independent of p53 and c-erbB2.
Our data were in agreement with Lemoine et al (I1992a) for p53 and
c-erbB2. but not forEGFR. Travis et al ( 1996) andQuinn et al ( 1994)
did not findany association between c-erbB3 andc-erbB2. Gasparini
et al (1994) found a significant association with c-erbB2 in node-
negative breast carcinoma patients. which is different from the group
of patients in the present study. We have documented that a high
percentage of EGFR-positive (67%7c). c-erbB2-positive (67%). pS3-
positive (75%c) and cathepsin-D-positive (6(%)%) DCIS were strongly
positive for c-erbB3. Recent studies have shown that transfection of
cells with c-erbB3 andc-erbB2 reconstitutes ahigheraffinity binding,
receptor. which is capable of goenerating a tyrosine phosphory-lation
signal in response to heregulim. Furthermore. in cells expressing
c-erbB2 and c-erbB3. both proteins become tyrosine phosphorylated
upon interaction withheregulin (Sliwkowski et al. 1994). This hereg-
ulin-stimulated phosphorvlation of c-erbB3 is likely mediated bv
cross-phosphorylation ofthe c-erbB3 protein by thec-erbB2 receptor
tvTosine kinase (Kim et al. 1994: Sliw-kowski et al. 1994). It also has
been shown that the bindinc ofepidermal growth factor (EGF) to the
EGFR results in the activation of its protein tyrosine kinase activity
and the phosphorylation of the c-erbB3 protein on tyTosine residues
(Kim et al. 1994). From various studies. it has been noted that over-
expression ofEGFR and cathepsin-D has been associated with poor
prognosis (Lewis et al. 1990: Nicholson et al. 1990: Tandon et al.
1990: Winstanley et al. 1993). suggesting that coexpression of
c-erbB3 protein and these tumour markers in the same tumours mav
be useful to predict the outcome or status ofthe disease.
Presence of high levels of c-erbB3 in non-invasive. non-inva-
sive and invasive in the same lesions and invasive carcinomas may
indicate that c-erbB3 could be involved in the progression of
tumours from preinvasive to invasive stare. Furthermore. its asso-
ciation with established prognostic factors such as histologrical
arade and with tumour markers includinc EGFR and cathepsin-D
may suggest that c-erbB3 could have potential to be a prognostic
indicator for breast cancer. However. other studies on a greater
number of patients. with clinical follow-up. are needed to demon-
strate the usefulness ofthis new marker.
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